HR
AYLA

Howe & Rusling’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Howe & Rusling’s Portfolio AYLA Stock Details AYLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-75
Closed – – 1232
2022
Q2 		$0 Buy
+75
New +$171 ﹤0.01% 1198

Other funds holding AYLA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Howe & Rusling's AYLA Position: Q3 2022 in Review

Howe & Rusling sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q3 2022, closing a stake of 75 shares.

Howe & Rusling first reported a position in AYLA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 14 funds tracked by Wall St. Rank hold AYLA as of Q3 2022.

  • Howe & Rusling reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 75 Ayala Pharmaceuticals, Inc. Common Stock shares in Q3 2022.
  • Howe & Rusling first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Howe & Rusling's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.